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Editorial 
The Challenge of Invasive Aspergillosis: 
Increasing Numbers in Dive&e Patient Groups 
Paul E. Verweij, MD, PhD;* and David K. Denning, MD:.. 
The fungus Aspergillus was first described in 1729 by 
Micheli,’ who, in naming the fungus, acknowledged the 
resemblance of the conidial head of Aspergilhs, with its 
radiating chains of spores, to an aspergillum, a brush used 
for sprinkling holy water. The first human case of 
aspergilloma was described in 1842 by Bennett2 who 
observed regular “vegetable structures” in tuberculous 
cavities in a patient who had died from pulmonary tuber- 
culosis. Many early cases were found in patients with 
tuberculosis, or those with a high occupational risk, such 
as in pigeon-crammers and wig-combers. Some of these 
cases were invasive, but most were aspergillomas. The 
ability of Aspergillus species to cause opportunistic infec- 
tion in immunocompromised patients was first described 
by Rankin His report of disseminated aspergillosis and 
candidiasis in a patient with agranulocytosis in the United 
Kingdom was published in 1953. However, it was not 
until 1970, when the clinical and histopathologic features 
of this disease were described in 98 patients, that the 
stage was set for any modern concepts of this devastat- 
ing opportunistic infection.* 
Since 1970, a number of autopsy studies have been 
published which indicate that the epidemiology of inva- 
sive fungal infections in immunocompromised patients 
is changing.Twenty years ago autopsy studies found 
Cundida to be the predominant path0gen.j However, 
studies of autopsy cases from Europe, the United States, 
and Japan show that the number of patients dying from 
invasive aspergillosis has increased significantly over 
the past 20 years.j-’ A recent remarkable autopsy study, 
performed in Germany, of more than 8000 cases showed 
Aspergillus to have become the leading pathogen, caus- 
ing up to 60% of fungal infections in the most recent 
period studied, while the number of cases with inva- 
sive candidiasis had declined.8 This was a relatively unbi- 
ased sample, as the autopsy rate in the institution was 
70% and microscopic evidence of fungal infection was 
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sought in all cases. A significant increase was noted for 
all high-risk populations and fungal infections were 
detected in 7% of all (unselected) autopsies in 1992.’ 
The increase in the number of cases among patients 
with hematologic malignancies in consolidation or main- 
tenance phase and among those treated with cortico- 
steroids is particularly notable .8,9 The underlying disease 
or condition greatly determines the level of risk for 
patients to become infected by Aspergillus species 
(Table l).” However, the frequency of cases observed 
by individual physicians may vary greatly for different 
patient groups, depending on the risk period. For some 
patients this is life-long, such as patients with acquired 
immunodeficiency syndrome (AIDS) or chronic granu- 
lomatous disease, whereas in other patient groups, such 
as those treated for acute myeloid leukemia, the risk 
period is highest for only several weeks. 
Invasive aspergillosis usually affects the lungs, sinuses, 
or tracheobronchial tree. Pulmonary or sinus disease may 
be acute or chronic, and the pace with which the disease 
progresses varies greatly Some patients die within 7 to 10 
days of first symptoms or radiologic abnormality; others 
can present 2 or 3 months after symptoms first appear. 
The pattern and degree of immunosuppression usually 
determines the rapidity of the course, so that invasive 
aspergillosis in corticosteroid-treated and profoundly neu- 
tropenic patients progresses more rapidly. A large num- 
ber of unusual manifestations of invasive aspergillosis 
continue to be reported, including, for example, postop- 
erative ocular and neurosurgery infections, Aspergillus 
prostatitis and peritonitis, breast implants and catheter 
device infections, and infection of the posterior medi- 
astinum and unusual bony sites.11-17 In addition, patients 
without conventional risk factors, including neonates or 
patients with systemic lupus erythematosus, or follow- 
ing drowning, or those with multiple myeloma are 
acquiring the disease.*8-21 
The diagnosis of invasive aspergillosis is difficult to 
establish since specimens for histology and culture, nec- 
essary to prove tissue invasion by the fungus, are often 
difficult to obtain in clinical practice. Although, over a 
period of 14 years the number of patients diagnosed ante- 
mortem increased from 7% to 32%, at present, the major- 
ity of Aspergilhs infections still remain undetected during 
life.8,22 Circumstantial evidence of infection can be 
obtained by culture and cytology of respiratory tract 
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Table 1. Spectrum of Patient Groups or Conditions with Increased Risk of Invasive Aspergillus infection Categorized by Infection Risk 
High Moderate Low 
(>lO%) (l-10%) (<l%) Negligible 
Chronic granulomatous disease AIDS patients Systemic lupus erythematosus Normal healthy persons 
Lung transplant recipients Liver, heart, or pancreas transplant on prednisolone Hospitalized patients without 
Acute myeloid leukemia recipients Diabetes mellitus neutropenia or treatment with 
(in unprotected air) Acute myeloid leukemia Alcoholism corticosteroids or other risk 
Allogeneic BMT recipients (in protected environment) Corticosteroid treatment conditions 
with GVHD > grade II Allogeneic BMT recipients Patients treated for solid tumors 
without GVHD or grade I Intensive care patients 
Autologous BMT recipients Agammaglobulinemia 
Intensive care patients on steroids Kidney transplant recipients 
Severe combined Influenza 
immunodeficiency syndrome Surgery in contaminated operating 
Lymphoma room air 
Major burn (e.g., > 30%) Major trauma 
BMT = bone marrow transplantation; GVHD = graft-versus-host disease. 
specimens, serology, or imaging techniques. New diag- 
nostic methods presently under investigation include the 
detection of Aspergillus DNA, or antigens, and high-res- 
olution computed tomography (CT).23~24 The improved 
sensitivity of these tests and procedures may allow for the 
early detection of the disease, especially when the meth- 
ods are combined. A recently published study showed 
that early thoracic CT scans of febrile neutropenic 
patients and culture and antigen detection of bron- 
choalveolar lavage fluid improved the prognosis of inva- 
sive aspergillosis when combined with early antifungal 
therapy and adjuvant thoracic surgery.25 A more aggres- 
sive approach to diagnosing fungal infections may be 
warranted not only to obtain the diagnosis at an early 
stage of disease but also to identify the pathogen caus- 
ing disease, since the number of invasive infections by 
molds other than Aspergillus fumigatus is increasing.* 
Only 34% of patients who receive treatment for inva- 
sive aspergillosis show a favorable response, and the 
crude mortality is 86/o O .26 Perhaps this high mortality is not 
surprising, given the difficulties of establishing the diag- 
nosis and the poor therapeutic responsesThe prognosis 
of invasive aspergillosis is determined by many factors, 
most importantly, by the response of the underlying dis- 
ease to therapyThe detection of in vitro and in vivo resis- 
tance among A. fumigatus to itraconazole has added to 
the factors that may reduce the probability of surviving 
the infection.27,28 Reproducible and meaningful in vitro 
susceptibility tests need to be developed, to establish the 
frequency of resistance among A. fumigatus to ampho- 
tericin B and itraconazole. These tests may be used to 
help guide antifungal therapy, since the choice of anti- 
fungal agent is often critical in severely immunocom- 
promised patients. 
The autopsy performed on the first reported granu- 
locytopenic patient with disseminated invasive aspergiuo- 
sis, in 1953, revealed that besides invasive aspergillosis the 
patient had suffered from a concurrent disseminated 
infection by Candida species (moniliasis).* Although 
now, 45 years later, both pathogens still account for the 
majority of invasive fungal infections, the changes in epi- 
demiology indicate that attempts to control fungal infec- 
tions have been partially successful for Candida but have 
thus far failed for AspergiZZus.The increasing number of 
cases and the high mortality associated with invasive 
aspergillosis underscores the necessity for further devel- 
opment and evaluation of rapid diagnostic techniques 
for different patient groups, the development of repro- 
ducible and meaningful in vitro susceptibility tests, and 
randomized studies for prevention of and treatment for 
invasive aspergillosis. 
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